Aeterna Zentaris to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
08 September 2021 - 10:00PM
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a
specialty biopharmaceutical company developing and commercializing
a diversified portfolio of pharmaceutical and diagnostic products,
today announced that Dr. Klaus Paulini, Chief Executive Officer of
Aeterna, will present at the virtual H.C. Wainwright 23rd Annual
Global Investment Conference taking place September 13-15, 2021.
In addition to the presentation, management will
be available to participate in virtual one-on-one meetings with
qualified members of the investor community who are registered to
attend the conference. For more information about the conference,
please visit the conference website.
A video webcast of the presentation will be
available for viewing on-demand beginning Monday, September 13,
2021, at 7:00 AM ET for those registered for the event and will be
accessible on the Events page in the Investors section of the
Company’s website (www.zentaris.com). The webcast replay will be
archived for 90 days following the event.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty
biopharmaceutical company developing and commercializing a
diversified portfolio of pharmaceutical and diagnostic products
focused on areas of significant unmet medical need. The Company's
lead product, macimorelin (Macrilen™), is the first and only U.S.
FDA and European Commission approved oral test indicated for the
diagnosis of adult growth hormone deficiency (AGHD). The Company is
leveraging the clinical success and compelling safety profile of
macimorelin to develop it for the diagnosis of childhood-onset
growth hormone deficiency (CGHD) in collaboration with Novo
Nordisk. The Company is also leveraging the clinical success and
compelling safety profile of macimorelin to develop it for the
diagnosis of childhood-onset growth hormone deficiency (CGHD), an
area of significant unmet need.
Aeterna Zentaris is dedicated to the development
of therapeutic assets and has recently taken steps to establish a
growing preclinical pipeline to potentially address unmet medical
needs across a number of indications, including neuromyelitis
optica spectrum disorder (NMOSD), hypoparathyroidism and
amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease).
Additionally, the Company is developing an oral prophylactic
bacterial vaccine against SARS-CoV-2, the virus that causes
COVID-19.
For more information, please
visit www.zentaris.com and connect with the Company
on Twitter, LinkedIn and Facebook.
Investor Contact:
Jenene ThomasJTC TeamT (US): +1 (833) 475-8247E:
aezs@jtcir.com
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Mar 2024 to Mar 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Mar 2023 to Mar 2024